NYSE:RCUSBiotechs
Arcus Biosciences (RCUS): Reassessing Valuation After Domvanalimab Trial Discontinuation and Casdatifan Pipeline Shift
Arcus Biosciences (RCUS) just shook up its pipeline strategy by scrapping the high profile Phase 3 STAR-221 gastric cancer trial after an interim look showed no survival benefit for its domvanalimab combo.
See our latest analysis for Arcus Biosciences.
Despite the headline setback in gastric cancer, investors seem to be looking through the domvanalimab news to Arcus Biosciences longer term pipeline potential. The share price is $23.22, with a powerful 90 day share price return of 87.41...